prednisone has been researched along with Scleritis in 64 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Scleritis: Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anterior and posterior scleritis may complicate the use of topical mitomycin C during trabeculectomy, Prompt diagnosis and treatment reverses the inflammation, maintaining the success of the surgical procedure." | 7.69 | Scleritis after glaucoma filtering surgery with mitomycin C. ( Fourman, S, 1995) |
| "Six patients with diffuse or nodular scleritis that did not respond satisfactorily to oral indomethacin or prednisone used alone required a combination of these two drugs to achieve a complete clinical response." | 7.67 | Treatment of scleritis with combined oral prednisone and indomethacin therapy. ( Mondino, BJ; Phinney, RB, 1988) |
| " The primary outcome was complete control of inflammation on prednisone ≤10 mg/day, sustained for ≥30 days." | 3.91 | Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases. ( Artornsombudh, P; Begum, H; Bhatt, NP; Daniel, E; Dreger, K; Foster, CS; Gangaputra, SS; Jabs, DA; Joffe, MM; Kempen, JH; Levy-Clarke, GA; Newcomb, CW; Nussenblatt, RB; Pujari, SS; Rosenbaum, JT; Sen, HN; Suhler, EB; Thorne, JE, 2019) |
| "Azathioprine was moderately effective as a single corticosteroid-sparing immunosuppressive agent in terms of control of inflammation and corticosteroid-sparing benefits, but required several months to achieve treatment goals; it seems especially useful for patients with intermediate uveitis." | 3.75 | Azathioprine for ocular inflammatory diseases. ( Foster, CS; Jabs, DA; Kempen, JH; Levy-Clarke, GA; Liesegang, TL; Newcomb, CW; Nussenblatt, RB; Pasadhika, S; Pujari, SS; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2009) |
"Ability to control ocular inflammation and to taper prednisone to | 3.74 | Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. ( Dunn, JP; Galor, A; Jabs, DA; Kedhar, SR; Leder, HA; Peters, GB; Thorne, JE, 2008) | |
| " Three groups of patients were prospectively evaluated: Group I: 15 patients with Wegener's granulomatosis and 4 patients with severe scleritis received a single dose cyclophosphamide (15 mg/kg bw/day) and 250 mg prednisone i." | 3.70 | Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). ( Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O, 1999) |
| "Anterior and posterior scleritis may complicate the use of topical mitomycin C during trabeculectomy, Prompt diagnosis and treatment reverses the inflammation, maintaining the success of the surgical procedure." | 3.69 | Scleritis after glaucoma filtering surgery with mitomycin C. ( Fourman, S, 1995) |
| "Six patients with diffuse or nodular scleritis that did not respond satisfactorily to oral indomethacin or prednisone used alone required a combination of these two drugs to achieve a complete clinical response." | 3.67 | Treatment of scleritis with combined oral prednisone and indomethacin therapy. ( Mondino, BJ; Phinney, RB, 1988) |
| "Oral prednisone was restarted to treat active lesions during bouts of inflammation." | 2.53 | Ocular Manifestations of Inherited Phospholipase-Cγ2-Associated Antibody Deficiency and Immune Dysregulation. ( Dana, R; Di Zazzo, A; Florakis, GJ; Tahvildari, M, 2016) |
| "Pain is historically considered a cardinal sign of acute inflammation and a predominant symptom of IOIS." | 2.46 | Idiopathic orbital inflammatory syndrome without pain: a case report. ( Boothe, KH; Eckermann, DR; Musick, AN; Slagle, AM; Slagle, WS, 2010) |
| "Nodular anterior scleritis is an uncommon presentation of tuberculosis (TB)." | 1.42 | Anterior tuberculous scleritis: A diagnostic challenge. ( Artaraz, J; del Rio, R; Fonollosa, A; Ruiz-Arruza, I; Silva-Ribeiro, AR; Vargas-Kelsh, JG, 2015) |
| "A patient diagnosed with necrotizing scleritis, c-ANCA+ an orbital pseudotumour, and possible multiple sclerosis in 2003 was treated with oral cyclophosphamide and steroids with partial response." | 1.40 | [C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab]. ( Aldasoro-Cáceres, I; Aldasoro-Cáceres, V; Ibáñez-Bosch, R; Murié-Fernández, M; Pérez-Moreiras, JV, 2014) |
| "Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce." | 1.40 | Five-year outcome in immune-mediated scleritis. ( Bernauer, W; Brunner, M; Pleisch, B, 2014) |
| " Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively." | 1.36 | Mycophenolate mofetil for ocular inflammation. ( Daniel, E; Foster, CS; Jabs, DA; Kaçmaz, RO; Kempen, JH; Levy-Clarke, GA; Newcomb, CW; Nussenblatt, RB; Pujari, SS; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2010) |
| " Dosing is less frequent than many medications currently available." | 1.35 | Rituximab for treatment of ocular inflammatory disease: a series of four cases. ( Choi, D; Kurz, PA; Rosenbaum, JT; Suhler, EB, 2009) |
| "Posterior scleritis is an unusual disease that may cause serious ocular inflammation and potentially blinding consequences." | 1.34 | Isolated bilateral posterior scleritis after eye trauma. ( Ramirez-Ortiz, MA; Vasquez-Resendis, A, 2007) |
| " Adverse events observed after treatment with chloroquine or prednisone (chloroquine maculopathy,cataract, glaucoma) are related to dosage and duration of the treatment." | 1.34 | [Ocular changes and general condition in lupus erythematosus (SLE)--own observation]. ( Brydak-Godowska, J, 2007) |
| "Although scleritis has not been reported as a tubulointerstitial nephritis-associated ocular inflammation, it may be part of the possible spectrum of ocular inflammation occurring as part of the TINU syndrome." | 1.33 | Recurrent nodular scleritis preceding an adult TINU syndrome. ( Daniel, E; Gangaputra, S; Jabs, DA; Kempen, JH, 2006) |
| "Scleritis was the first manifestation of sarcoidosis in two of the patients and the diagnosis of sarcoidosis was confirmed with a conjunctival biopsy." | 1.32 | Scleritis associated with sarcoidosis. ( Akova, YA; Bilezikçi, B; Dursun, D, 2004) |
| "Patients with necrotizing scleritis and posterior scleritis were more likely to be treated with oral corticosteroids or immunosuppressive drugs (90% and 100%, respectively) than were patients with diffuse anterior scleritis and nodular anterior scleritis (56." | 1.31 | Episcleritis and scleritis: clinical features and treatment results. ( Dunn, JP; Jabs, DA; Marsh, MJ; Mudun, A, 2000) |
| " Because of that, there was no need to increase dosage nor to switch systemic immunosuppressors." | 1.31 | [Transeptal steroids in necrotizing scleritis]. ( Folch Ramos, J; Sainz De La Maza Serra, M, 2001) |
| "Episcleritis is a rare occurrence in childhood, especially in children younger than 5 years of age." | 1.30 | Episcleritis in childhood. ( Read, RW; Sherry, DD; Weiss, AH, 1999) |
| "Sarcoidosis was confirmed by biopsy of an enlarged parotid gland." | 1.29 | Posterior scleritis with annular ciliochoroidal detachment. ( Barnhorst, DA; Caravella, LP; Dodds, EM; Lavertu, P; Lowder, CY; White, DE, 1995) |
| "Wegener's granulomatosis is a well-defined systemic vasculitic syndrome that primarily affects the upper and lower respiratory tracts and the kidney." | 1.29 | Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis. ( Gal, AA; LiVolsi, VA; Masor, JJ, 1994) |
| "A case of a patient with necrotizing scleritis of both eyes who had been under medical observation and who had undergone medical treatment for five years is described." | 1.29 | [Necrotizing scleritis--case report of a patient effectively treated with high doses of corticosteroids]. ( Chorabik, E, 1996) |
| "Patients with colitis or ileocolitis were more likely to suffer from ocular inflammation (23." | 1.28 | Ocular inflammation in Crohn's disease. ( Murray, AD; Salmon, JF; Wright, JP, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.13) | 18.7374 |
| 1990's | 16 (25.00) | 18.2507 |
| 2000's | 24 (37.50) | 29.6817 |
| 2010's | 20 (31.25) | 24.3611 |
| 2020's | 2 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, J | 1 |
| Tang, B | 1 |
| Shi, Y | 1 |
| Zou, P | 1 |
| Zhang, G | 1 |
| Ding, Y | 1 |
| Xiao, R | 1 |
| Agranat, JS | 1 |
| Moussa, K | 1 |
| Aronow, ME | 1 |
| Breazzano, MP | 1 |
| Chen, RWS | 1 |
| Valera-Cornejo, DA | 1 |
| García-Roa, M | 1 |
| Romero-Morales, V | 1 |
| Tsui, E | 1 |
| Sarrafpour, S | 1 |
| Modi, YS | 1 |
| Gangaputra, SS | 1 |
| Newcomb, CW | 3 |
| Joffe, MM | 1 |
| Dreger, K | 1 |
| Begum, H | 1 |
| Artornsombudh, P | 2 |
| Pujari, SS | 3 |
| Daniel, E | 4 |
| Sen, HN | 1 |
| Suhler, EB | 6 |
| Thorne, JE | 9 |
| Bhatt, NP | 1 |
| Foster, CS | 7 |
| Jabs, DA | 9 |
| Nussenblatt, RB | 5 |
| Rosenbaum, JT | 7 |
| Levy-Clarke, GA | 5 |
| Kempen, JH | 7 |
| Aldasoro-Cáceres, V | 1 |
| Aldasoro-Cáceres, I | 1 |
| Pérez-Moreiras, JV | 1 |
| Murié-Fernández, M | 1 |
| Ibáñez-Bosch, R | 1 |
| Faez, S | 1 |
| Lobo, AM | 1 |
| Unizony, SH | 1 |
| Stone, JH | 2 |
| Papaliodis, GN | 1 |
| Sobrin, L | 1 |
| Bernauer, W | 2 |
| Pleisch, B | 1 |
| Brunner, M | 2 |
| Liu, X | 1 |
| Kuriyan, AE | 1 |
| Amescua, G | 1 |
| Schuler, S | 1 |
| Vargas-Kelsh, JG | 1 |
| Fonollosa, A | 1 |
| Artaraz, J | 1 |
| del Rio, R | 1 |
| Silva-Ribeiro, AR | 1 |
| Ruiz-Arruza, I | 1 |
| Durrani, K | 1 |
| Ying, GS | 2 |
| Kacmaz, RO | 2 |
| Di Zazzo, A | 1 |
| Tahvildari, M | 1 |
| Florakis, GJ | 1 |
| Dana, R | 1 |
| Galor, A | 1 |
| Leder, HA | 1 |
| Kedhar, SR | 2 |
| Dunn, JP | 3 |
| Peters, GB | 1 |
| Oono, S | 1 |
| Kurimoto, T | 1 |
| Oku, H | 1 |
| Mimura, O | 1 |
| Kurz, PA | 1 |
| Choi, D | 1 |
| Farooq, O | 1 |
| Buccilli, A | 1 |
| Varma, C | 1 |
| Reidy, JJ | 1 |
| Faden, H | 1 |
| Fugate, JE | 1 |
| Smith, JH | 1 |
| Claassen, DO | 1 |
| Pasadhika, S | 1 |
| Liesegang, TL | 1 |
| Kesen, MR | 1 |
| Edward, DP | 1 |
| Rao, NA | 1 |
| Sugar, J | 1 |
| Tessler, HH | 1 |
| Goldstein, DA | 1 |
| Slagle, WS | 1 |
| Boothe, KH | 1 |
| Musick, AN | 1 |
| Eckermann, DR | 1 |
| Slagle, AM | 1 |
| Payne, JF | 1 |
| Srivastava, SK | 1 |
| Wells, JR | 1 |
| Grossniklaus, HE | 1 |
| Kroshinsky, D | 1 |
| Nazarian, RM | 1 |
| Maschi, C | 1 |
| Tieulié, N | 1 |
| Gastaud, P | 1 |
| Baillif, S | 1 |
| Mellado, F | 1 |
| Talesnik, E | 1 |
| Castiglione, E | 1 |
| Udoetuk, JD | 1 |
| Dai, Y | 1 |
| Gangaputra, S | 2 |
| Paulus, YM | 1 |
| Cockerham, KP | 1 |
| Cockerham, GC | 1 |
| Gratzinger, D | 1 |
| Hernandez, MI | 1 |
| Rencic, A | 1 |
| Nousari, HC | 1 |
| Altan-Yaycioglu, R | 1 |
| Akova, YA | 2 |
| Kart, H | 1 |
| Cetinkaya, A | 1 |
| Yilmaz, G | 1 |
| Aydin, P | 1 |
| Crovetto, M | 1 |
| Solano, D | 1 |
| Centeno, J | 1 |
| Androudi, S | 2 |
| Iaccheri, B | 1 |
| Brazitikos, P | 1 |
| Papadaki, T | 1 |
| Dursun, D | 1 |
| Bilezikçi, B | 1 |
| Gonçalves, RM | 1 |
| Curi, AL | 1 |
| Campos, WR | 1 |
| Oréfice, F | 1 |
| Machado, DO | 1 |
| Levy, J | 1 |
| Schneck, M | 1 |
| Erlich, Y | 1 |
| Lifshitz, T | 1 |
| Qazi, FA | 1 |
| Nguyen, QD | 1 |
| Ramirez-Ortiz, MA | 1 |
| Vasquez-Resendis, A | 1 |
| Starosta, MA | 1 |
| Brandwein, SR | 1 |
| Belair, ML | 1 |
| Jun, AS | 1 |
| Sulkowski, M | 1 |
| Ahmed, M | 1 |
| Niffenegger, JH | 1 |
| Jakobiec, FA | 1 |
| Ben-Arie-Weintrob, Y | 1 |
| Gion, N | 1 |
| Folberg, R | 1 |
| Raizman, MB | 1 |
| Margo, CE | 1 |
| Smith, ME | 1 |
| McLean, IW | 1 |
| Caya, JG | 1 |
| Brydak-Godowska, J | 1 |
| Dodds, EM | 2 |
| Lowder, CY | 1 |
| Barnhorst, DA | 1 |
| Lavertu, P | 1 |
| Caravella, LP | 1 |
| White, DE | 1 |
| Casoli, P | 1 |
| Tumiati, B | 1 |
| Masor, JJ | 1 |
| Gal, AA | 1 |
| LiVolsi, VA | 1 |
| Gedde, SJ | 1 |
| Augsburger, JJ | 1 |
| Zeitouni, AG | 1 |
| Tewfik, TL | 1 |
| Schloss, M | 1 |
| Tucker, SM | 1 |
| Hurwitz, JJ | 1 |
| Pavlin, CJ | 1 |
| Howarth, DJ | 1 |
| Nianiaris, N | 1 |
| Kersten, RC | 1 |
| Kulwin, DR | 1 |
| Chorabik, E | 1 |
| Fourman, S | 1 |
| Irarrázaval, LA | 1 |
| Scarfone, A | 1 |
| Gáspari, E | 1 |
| Reinhardt, W | 1 |
| Sauter, V | 1 |
| Jockenhövel, F | 1 |
| Kummer, G | 1 |
| Uppenkamp, M | 1 |
| Witzke, O | 1 |
| Philipp, T | 1 |
| Reinwein, D | 1 |
| Mann, K | 1 |
| Read, RW | 1 |
| Weiss, AH | 1 |
| Sherry, DD | 1 |
| Mudun, A | 1 |
| Marsh, MJ | 1 |
| Smith, JR | 1 |
| Sainz De La Maza Serra, M | 1 |
| Folch Ramos, J | 1 |
| Bozkir, N | 1 |
| Stern, GA | 1 |
| Glasser, DB | 1 |
| Bellor, J | 1 |
| Sacks, RD | 1 |
| Stock, EL | 1 |
| Crawford, SE | 1 |
| Greenwald, MJ | 1 |
| O'Grady, RB | 1 |
| Salmon, JF | 1 |
| Wright, JP | 1 |
| Murray, AD | 1 |
| Lightman, S | 1 |
| Watson, P | 1 |
| Mondino, BJ | 1 |
| Phinney, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial[NCT01829295] | Phase 3 | 216 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial[NCT01092533] | Phase 3 | 44 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study[NCT03465111] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)[NCT01835132] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase I/II Study to Investigate Subconjunctival Sirolimus for the Treatment of Active Autoimmune Non-Necrotizing Anterior Scleritis[NCT01517074] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate for patients who crossed over to other medication following treatment failure at 6 months (or earlier). (NCT01829295)
Timeframe: 6 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Switched Over to Methotrexate | 20 |
| Switched Over to Mycophenolate Mofetil | 7 |
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate in patients who were a treatment success at the primary outcome of 6 months. (NCT01829295)
Timeframe: 12 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methotrexate | 48 |
| Mycophenolate Mofetil | 40 |
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate. (NCT01829295)
Timeframe: 6 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methotrexate | 64 |
| Mycophenolate Mofetil | 56 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Final Visit
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.33 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 12
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.00 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 16
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.56 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 2
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 0.67 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 20
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.33 |
Mean Change in Intraocular pressure (IOP) is measured and reported as change in IOP between baseline and 24 weeks in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 24
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 0.78 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 28
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.11 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 32
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 2.67 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 36
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 2.17 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 0.67 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 40
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 0.50 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.83 |
"This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62.~Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg)." (NCT01835132)
Timeframe: Baseline and Week 52A
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | -0.67 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 54
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.33 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 58
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.33 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 62
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 0.67 |
Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg). (NCT01835132)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Mean) |
|---|---|
| Gevokizumab | 1.11 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Final Visit
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -2.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 12
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 0.11 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 16
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 1.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 2
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -1.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 20
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 1.33 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 24
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -0.67 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 28
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 1.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 32
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 3.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 36
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 1.83 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 4
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -1.78 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 40
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 2.67 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 52
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 0.17 |
"This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62.~Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20." (NCT01835132)
Timeframe: Baseline and Week 52A
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -8.00 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 54
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -0.67 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 58
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -1.33 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 62
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | -1.33 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Baseline and Week 8
| Intervention | ETDRS letters (Mean) |
|---|---|
| Gevokizumab | 0.78 |
Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show). (NCT01835132)
Timeframe: Baseline and Week 16
| Intervention | participants (Number) |
|---|---|
| Gevokizumab | 6 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01835132)
Timeframe: Post-injection through study completion, up to 78 weeks per participant
| Intervention | participants (Number) |
|---|---|
| Gevokizumab | 0 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | letters read (Mean) |
|---|---|
| Study Eye | -0.25 |
| Fellow Eye | -2.25 |
For participants who demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | Days (Mean) |
|---|---|
| Sirolimus | 65.3 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | letters read (Median) |
|---|---|
| Study Eye | 0.00 |
| Fellow Eye | -2.50 |
Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period). (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 3 |
Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show) (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 3 |
A substantial rise in intraocular pressure can be defined as ≥10 mmHg change in pressure. (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 0 |
"The primary efficacy outcome was a 2-step reduction in scleritis grading out of a scale of 0 to 4+ (where 0.5+ is recognized as an ordinal step between 1+ and 0+).~Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show)." (NCT01517074)
Timeframe: Baseline and Week 8
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 5 |
(NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 2 |
(NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 0 |
Four (4) out of 5 participants were on immunosuppressive medications at enrollment. (NCT01517074)
Timeframe: Week 16 and Week 52
| Intervention | participants (Number) |
|---|---|
| Sirolimus | 1 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT01517074)
Timeframe: Baseline to Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Eye | 0 |
| Fellow Eye | 1 |
Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show) (NCT01517074)
Timeframe: Baseline and Week 52
| Intervention | score on a scale (Number) | |||
|---|---|---|---|---|
| Participant 001 | Participant 002 | Participant 003 | Participant 005 | |
| Scleral Inflammation Score at Baseline | 3 | 1 | 3 | 3 |
| Scleral Inflammation Score at Week 52 | 0 | 0 | 0 | 0 |
| Step Changes in Scleral Inflammation at Week 52 From Baseline | -4 | -2 | -4 | -4 |
3 reviews available for prednisone and Scleritis
| Article | Year |
|---|---|
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Panuveitis; Polymyalgia Rheumatica; Pred | 2016 |
Ocular Manifestations of Inherited Phospholipase-Cγ2-Associated Antibody Deficiency and Immune Dysregulation.
Topics: Administration, Oral; Antirheumatic Agents; Conjunctivitis; Corneal Diseases; Drug Therapy, Combinat | 2016 |
Idiopathic orbital inflammatory syndrome without pain: a case report.
Topics: Aged; Conjunctival Diseases; Dacryocystitis; Diagnosis, Differential; Edema; Humans; Inflammation; M | 2010 |
61 other studies available for prednisone and Scleritis
| Article | Year |
|---|---|
Rosai-Dorfman Disease with Systemic Multiple Involvement: A Case Report.
Topics: Administration, Oral; Adrenal Cortex Hormones; Biopsy, Needle; Blood Sedimentation; C-Reactive Prote | 2019 |
An Amelanotic Choroidal Mass in a Middle-aged Woman.
Topics: Choroid Neoplasms; Female; Fluorescein Angiography; Glucocorticoids; Humans; Intraocular Pressure; M | 2019 |
Scleritis With Uveal Effusion From Alirocumab.
Topics: Antibodies, Monoclonal, Humanized; Female; Glucocorticoids; Humans; Hypercholesterolemia; Middle Age | 2020 |
Surgically induced diffuse scleritis associated with choroidal detachment following phacoemulsification surgery.
Topics: Choroidal Effusions; Humans; Inflammation; Male; Phacoemulsification; Prednisone; Scleritis; Visual | 2022 |
Posterior Scleritis with Choroidal Effusion Secondary to Herpes Zoster Ophthalmicus.
Topics: Acyclovir; Aged; Antiviral Agents; Choroid Diseases; Drug Therapy, Combination; Female; Glucocortico | 2018 |
Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Glucocorticoids; Humans | 2019 |
[C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab].
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Muri | 2014 |
Five-year outcome in immune-mediated scleritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Autoantibodies; Autoantigens; Female; Follow-Up Studies; Glucoco | 2014 |
A painful red eye.
Topics: Administration, Oral; Adult; Antibodies, Antineutrophil Cytoplasmic; Biopsy; Conjunctivitis; Eye Pai | 2015 |
Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis.
Topics: Acyclovir; Antiviral Agents; Aqueous Humor; Arthritis, Rheumatoid; Drug Therapy, Combination; Eye In | 2016 |
Anterior tuberculous scleritis: A diagnostic challenge.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Biopsy; Bronchoalveolar Lavag | 2015 |
Adalimumab for Ocular Inflammation.
Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Child, Preschool; Cohort Studi | 2017 |
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Azathioprine; Child; Female; Glucocorti | 2008 |
Adult T-cell leukemia presenting with episcleritis and secondary glaucoma.
Topics: Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Conjunctivit | 2009 |
Rituximab for treatment of ocular inflammatory disease: a series of four cases.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Dru | 2009 |
Posterior scleritis: a rare pediatric disorder.
Topics: Child; Female; Glucocorticoids; Humans; Prednisone; Rare Diseases; Scleritis; Tomography, X-Ray Comp | 2009 |
Bilateral cochlear enhancement in Cogan syndrome.
Topics: Adult; Autoimmune Diseases; Cerebral Arteries; Cochlea; Diagnosis, Differential; Functional Laterali | 2009 |
Azathioprine for ocular inflammatory diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Female; Follow-Up Studies; Humans; | 2009 |
Atypical infectious nodular scleritis.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Therapy, Combination; Female; Genome, Bacterial; Humans; | 2009 |
Mycophenolate mofetil for ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Female; | 2010 |
Rosai-Dorfman disease simulating nodular scleritis and panuveitis.
Topics: Diagnosis, Differential; Female; Histiocytes; Histiocytosis, Sinus; Humans; Immunoenzyme Techniques; | 2011 |
Case records of the Massachusetts General Hospital. Case 22-2011. A 79-year-old man with a rash, arthritis, and ocular erythema.
Topics: Aged; Arthritis; Atrial Fibrillation; Autoimmune Diseases; Complement System Proteins; Diagnosis, Di | 2011 |
Use of hydroxychloroquine in corticodependent and recurrent scleritis.
Topics: Adult; Antirheumatic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; | 2013 |
Azathioprine as monotherapy for scleritis in relapsing polychondritis.
Topics: Azathioprine; Child; Drug Therapy, Combination; Eye Pain; Female; Humans; Immunosuppressive Agents; | 2012 |
Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.
Topics: Cohort Studies; Female; Follow-Up Studies; Glucocorticoids; Humans; Hyperglycemia; Hypoglycemic Agen | 2012 |
IgG4-positive sclerosing orbital inflammation involving the conjunctiva: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Biopsy; C-Reactive Protein; | 2012 |
Severe scleritis and urticarial lesions.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Complement C3; Complement C4 | 2002 |
Posterior scleritis in psoriatic arthritis.
Topics: Aged; Arthritis, Psoriatic; Azathioprine; Drug Therapy, Combination; Female; Fluorescein Angiography | 2003 |
[Recurrent polychondritis: apropos of a case].
Topics: Aspirin; Autoimmune Diseases; Azathioprine; Biopsy; Carcinoma, Squamous Cell; Conjunctivitis; Cyclos | 2003 |
Bilateral chronic anterior uveitis & neuro-ophthalmologic manifestations in a patient with Churg-Strauss syndrome: an unusual ocular presentation.
Topics: Adult; Asthma; Chronic Disease; Churg-Strauss Syndrome; Cyclophosphamide; Drug Therapy, Combination; | 2004 |
Scleritis associated with sarcoidosis.
Topics: Aged; Anti-Inflammatory Agents; Conjunctiva; Female; Humans; Middle Aged; Prednisone; Recurrence; Sa | 2004 |
Posterior scleritis in Cogan's syndrome.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Choroid Diseases; Fluoresce | 2004 |
Sweet's syndrome presenting as acute episcleritis.
Topics: Adult; Glucocorticoids; Humans; Male; Prednisone; Scleritis; Sweet Syndrome | 2005 |
Mycophenolate mofetil therapy for inflammatory eye disease.
Topics: Adolescent; Adult; Aged; Child; Conjunctival Diseases; Drug Therapy, Combination; Female; Glucocorti | 2005 |
Mycophenolate mofetil therapy for inflammatory eye disease.
Topics: Adolescent; Adult; Aged; Child; Conjunctival Diseases; Drug Therapy, Combination; Female; Glucocorti | 2005 |
Mycophenolate mofetil therapy for inflammatory eye disease.
Topics: Adolescent; Adult; Aged; Child; Conjunctival Diseases; Drug Therapy, Combination; Female; Glucocorti | 2005 |
Mycophenolate mofetil therapy for inflammatory eye disease.
Topics: Adolescent; Adult; Aged; Child; Conjunctival Diseases; Drug Therapy, Combination; Female; Glucocorti | 2005 |
Recurrent nodular scleritis preceding an adult TINU syndrome.
Topics: Acute Disease; Female; Glucocorticoids; Humans; Indomethacin; Middle Aged; Nephritis, Interstitial; | 2006 |
Isolated bilateral posterior scleritis after eye trauma.
Topics: Azathioprine; Child; Conjunctiva; Drug Therapy, Combination; Eye Injuries; Eyelids; Female; Fluoresc | 2007 |
Clinical manifestations and treatment of rheumatoid pachymeningitis.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Brain; Female; Hearing | 2007 |
Scleritis and peripheral ulcerative keratitis with hepatitis C virus-related cryoglobulinemia.
Topics: Antiviral Agents; Corneal Ulcer; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Eye | 2007 |
Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Dacryocyst | 2008 |
[Ocular changes and general condition in lupus erythematosus (SLE)--own observation].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Female; Humans | 2007 |
Posterior scleritis with annular ciliochoroidal detachment.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Inflammatory Agents; Biopsy; Choroid Diseases; Ciliary Body | 1995 |
Cogan's syndrome: a new possible complication of antiphospholipid antibodies?
Topics: Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Drug Therapy, Combination; Female; Hearin | 1995 |
Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis.
Topics: Azathioprine; Eye Diseases; Female; Granulomatosis with Polyangiitis; Humans; Kidney; Middle Aged; P | 1994 |
Posterior scleritis as a fundus mass.
Topics: Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Middle Aged; Optic Disk; P | 1994 |
Cogan's syndrome: a review of otologic management and 10-year follow-up of a pediatric case.
Topics: Child; Follow-Up Studies; Hearing Loss, Bilateral; Humans; Keratitis; Male; Prednisone; Scleritis; S | 1993 |
Scleral melt after cryotherapy for conjunctival melanoma.
Topics: Aged; Conjunctival Neoplasms; Cryosurgery; Humans; Male; Melanoma; Melanosis; Postoperative Complica | 1993 |
MMC in ONS decompression.
Topics: Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Humans; Male; Mitomycin; Myelin S | 1996 |
[Necrotizing scleritis--case report of a patient effectively treated with high doses of corticosteroids].
Topics: Anti-Inflammatory Agents; Humans; Male; Middle Aged; Prednisone; Scleritis | 1996 |
Scleritis after glaucoma filtering surgery with mitomycin C.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Age | 1995 |
Bilateral posterior scleritis.
Topics: Adult; Anti-Inflammatory Agents; Fluorescein Angiography; Fundus Oculi; Humans; Macula Lutea; Male; | 1997 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexameth | 1999 |
Episcleritis in childhood.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Prescho | 1999 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Episcleritis and scleritis: clinical features and treatment results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2000 |
Case reports and small case series: scleritis occurring in association with Takayasu disease.
Topics: Adult; Aorta, Thoracic; Aortography; Aspirin; Blood Pressure; Drug Therapy, Combination; Female; Fol | 2001 |
[Transeptal steroids in necrotizing scleritis].
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; I | 2001 |
Ocular manifestations of the idiopathic hypereosinophilic syndrome.
Topics: Eosinophilia; Humans; Keratoconjunctivitis Sicca; Male; Middle Aged; Ocular Hypertension; Prednisone | 1992 |
Necrotizing scleritis of scleral flaps after transscleral suture fixation of an intraocular lens.
Topics: Arthritis, Rheumatoid; Cataract Extraction; Cyclophosphamide; Female; Humans; Lenses, Intraocular; M | 1992 |
Scleritis and Wegener's granulomatosis in children.
Topics: Adolescent; Blood Sedimentation; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Humans; | 1991 |
Ocular inflammation in Crohn's disease.
Topics: Adolescent; Adult; Aged; Anterior Eye Segment; Anti-Inflammatory Agents, Non-Steroidal; Child; Colit | 1991 |
Treatment of scleritis with combined oral prednisone and indomethacin therapy.
Topics: Administration, Oral; Drug Therapy, Combination; Humans; Indomethacin; Prednisone; Scleritis | 1989 |
Treatment of scleritis with combined oral prednisone and indomethacin therapy.
Topics: Administration, Oral; Drug Combinations; Female; Humans; Indomethacin; Male; Middle Aged; Prednisone | 1988 |